Related Experiment Video

Updated: Mar 29, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.5K

A placebo controlled trial for an NMO relapse prevention treatment: Ethical considerations

Rosamond Rhodes1

  • 1Icahn School of Medicine at Mount Sinai, One Gustave Levy Place, Box 1076, Annenberg 12-42, NY 10029, USA.

Multiple Sclerosis and Related Disorders
|November 23, 2015
PubMed

Insights

This study examines the ethics of a placebo-controlled trial for Neuromyelitis Optica (NMO) relapse prevention. It highlights lifelong participant impacts and standard ethical considerations like vulnerability, benefits, harms, and justice.

Area of Science:

  • Neurology
  • Clinical Trials
  • Bioethics

Background:

  • Neuromyelitis Optica (NMO) is a rare autoimmune disease affecting the central nervous system.
  • Relapse prevention is a critical aspect of managing NMO and improving patient outcomes.
  • Ethical considerations are paramount in clinical research, especially for vulnerable populations.

Purpose of the Study:

  • To evaluate the ethical acceptability of a proposed placebo-controlled trial for a new NMO relapse prevention intervention.
  • To identify and analyze often overlooked ethical factors in NMO clinical trials.
  • To discuss standard ethical principles in the context of NMO research.

Main Methods:

  • Ethical analysis of a proposed clinical trial design.
  • Review of existing literature on NMO and clinical trial ethics.
  • Consideration of stakeholder perspectives, including patients and the broader NMO community.

Main Results:

  • The paper identifies significant ethical challenges related to long-term implications for NMO trial participants.
  • It emphasizes the need to balance potential benefits against harms and ensure justice for all involved.
  • Standard ethical issues such as vulnerability and informed consent require careful attention.

Conclusions:

  • The ethical acceptability of the proposed NMO trial requires thorough consideration of unique patient factors.
  • A comprehensive ethical review must go beyond standard guidelines to address lifelong consequences.
  • Balancing scientific rigor with participant welfare is essential for responsible NMO research.
Keywords:
EvidenceJusticeNMOPlacebo controlled trialResearch ethics

More Related Videos

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research08:33

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Published on: January 5, 2024

1.9K
Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-409:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

12.1K

Related Concept Videos

Blinding01:11

Blinding

Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
4.1K
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
208
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
388
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.4K